Marcel H. N. Hoefnagel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marcel H. N. Hoefnagel has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Rob J. Vandebriel
Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
4 shared publications Coen A.L. Stalpers
Centre for Health Protection, National Institute for Public Health and the Environment, Bilthoven, the Netherlands; Faculty of Veterinary Medicine, Department of Biomolecular Health Sciences, Utrecht University, Utrecht, Netherlands; Quality Department, Medicines Evaluation Board, Utrecht, the Netherlands
3 shared publicationsCoenraad F.M. Hendriksen
Intravacc, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
3 shared publicationsArnoud M. Akkermans
RIVM, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
2 shared publicationsCharlotte de Wolf
Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands; Department of Infectious Diseases and Immunology, Utrecht University, The Netherlands
2 shared publicationsIrene A. Retmana
CBG-MEB, Graadt van Roggenweg 500, 3531 AH Utrecht, the Netherlands
2 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Elsevier in NAM Journal
- Vol. 2
Towards regulatory acceptance of 3D in vitro mucosal models in non-clinical vaccine development and market authorization
- 24 October 2026
- Published by Elsevier in NAM Journal
- Vol. 2
Open AccessTowards regulatory acceptance of 3D in vitro mucosal models in non-clinical vaccine development and market authorization
- Open Access
- 4 April 2026
- Published by Elsevier in Biologicals
- Vol. 94, 101885
Leveraging analytical and bioprocess platforms for biological product development and commercialization – A meeting report
- 4 April 2026
- Published by Elsevier in Biologicals
- Vol. 94, 101885
Open AccessLeveraging analytical and bioprocess platforms for biological product development and commercialization – A meeting report
- Open Access
- 19 April 2023
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 22 (1) , 369-377
Rational arguments for regulatory acceptance of consistency testing: benefits of non-animal testing over in vivo release testing of vaccines
There are rational arguments to replace existing in vivo potency and safety assays for batch release testing of vaccines with more advanced non-animal techniques to measure critical quality attribu...
- 19 April 2023
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 22 (1) , 369-377
Open AccessRational arguments for regulatory acceptance of consistency testing: benefits of non-animal testing over in vivo release testing of vaccines
There are rational arguments to replace existing in vivo potency and safety assays for batch release testing of vaccines with more advanced non-animal techniques to measure critical quality attribu...
- Open Access
- 22 September 2021
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 20 (10) , 1221-1233
Overcoming scientific barriers in the transition fromin vivoto non-animal batch testing of human and veterinary vaccines
Before release, vaccine batches are assessed for quality to evaluate whether they meet the product specifications. Vaccine batch tests, in particular of inactivated and toxoid vaccines, still large...
- 22 September 2021
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 20 (10) , 1221-1233
Open AccessOvercoming scientific barriers in the transition fromin vivoto non-animal batch testing of human and veterinary vaccines
Before release, vaccine batches are assessed for quality to evaluate whether they meet the product specifications. Vaccine batch tests, in particular of inactivated and toxoid vaccines, still large...
- Open Access
Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines
- Open Access
- 2 April 2020
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 7, 91
Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised
Regulatory T cells (Tregs) have a prominent role in the control of immune homeostasis. Pharmacological impact on their activity or balance with effector T cells could contribute to (impaired) clinical responses or adverse events. Monitoring treatment-related effects on T cell subsets may therefore be part of (pre-)clinical studies for medicinal products. However, the extent of immune monitoring performed in studies for marketing authorisation and the degree of correspondence with data available in the public domain is not known. We evaluated the presence of T cell immunomonitoring in 46 registration dossiers of monoclonal antibodies indicated for immune-related disorders and published scientific papers. We found that the depth of Treg analysis in registration dossiers was rather small. Nevertheless, data on treatment-related Treg effects are available in public academia-driven studies (post-registration) and suggest that Tregs may act as a biomarker for clinical responses. However, public data are fragmented and obtained with heterogeneity of experimental approaches from a diversity of species and tissues. To reveal the potential added value of T cell (and particular Treg) evaluation in (pre-)clinical studies, more cell-specific data should be acquired, at least for medicinal products with an immunomodulatory mechanism. Therefore, extensive analysis of T cell subset contribution to clinical responses and the relevance of treatment-induced changes in their levels is needed. Preferably, industry and academia should work together to obtain these data in a standardised manner and to enrich our knowledge about T cell activity in disease pathogenesis and therapies. This will ultimately elucidate the necessity of T cell subset monitoring in the therapeutic benefit-risk assessment.
- 2 April 2020
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 7, 91
Open AccessDawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised
Regulatory T cells (Tregs) have a prominent role in the control of immune homeostasis. Pharmacological impact on their activity or balance with effector T cells could contribute to (impaired) clinical responses or adverse events. Monitoring treatment-related effects on T cell subsets may therefore be part of (pre-)clinical studies for medicinal products. However, the extent of immune monitoring performed in studies for marketing authorisation and the degree of correspondence with data available in the public domain is not known. We evaluated the presence of T cell immunomonitoring in 46 registration dossiers of monoclonal antibodies indicated for immune-related disorders and published scientific papers. We found that the depth of Treg analysis in registration dossiers was rather small. Nevertheless, data on treatment-related Treg effects are available in public academia-driven studies (post-registration) and suggest that Tregs may act as a biomarker for clinical responses. However, public data are fragmented and obtained with heterogeneity of experimental approaches from a diversity of species and tissues. To reveal the potential added value of T cell (and particular Treg) evaluation in (pre-)clinical studies, more cell-specific data should be acquired, at least for medicinal products with an immunomodulatory mechanism. Therefore, extensive analysis of T cell subset contribution to clinical responses and the relevance of treatment-induced changes in their levels is needed. Preferably, industry and academia should work together to obtain these data in a standardised manner and to enrich our knowledge about T cell activity in disease pathogenesis and therapies. This will ultimately elucidate the necessity of T cell subset monitoring in the therapeutic benefit-risk assessment.
- 1 November 2018
- Published by Elsevier in Cytotherapy
- Vol. 20 (11) , 1289-1308
Regulatory perspective on in vitro potency assays for human dendritic cells used in anti-tumor immunotherapy
- 1 November 2018
- Published by Elsevier in Cytotherapy
- Vol. 20 (11) , 1289-1308
Regulatory perspective on in vitro potency assays for human dendritic cells used in anti-tumor immunotherapy